Idenix (IDIX) Enters Collaboration with Janssen Pharma for DAA HCV Evaluatlion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Wedbush Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Neutral
January 30, 2013 7:15 AM ESTWedbush downgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Outperform to Neutral with a price target of $6.00 (from $7.00).
The firm comments, "On Monday, Idenix announced a collaboration with JNJ for IDX719 (NS5A) to be paired with simeprevir (TMC435; PI) and TMC647055 (NNI) in... More
